Fecal S100A12 in Healthy Infants and Children

被引:18
作者
Day, A. S. [1 ,2 ,3 ]
Ehn, M. [3 ]
Gearry, R. B. [4 ]
Lemberg, D. A. [1 ,2 ]
Leach, S. T. [2 ]
机构
[1] Sydney Childrens Hosp, Dept Gastroenterol, Sydney, NSW 2034, Australia
[2] Univ New S Wales, Sch Womens & Childrens Hlth, Sydney, NSW 2052, Australia
[3] Univ Otago Christchurch, Dept Paediat, Christchurch 8140, New Zealand
[4] Univ Otago Christchurch, Dept Med, Christchurch 8140, New Zealand
关键词
INFLAMMATORY-BOWEL-DISEASE; NONINVASIVE MARKER; CALPROTECTIN; DIAGNOSIS; PROTEINS; RAGE;
D O I
10.1155/2013/873582
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background and Aims. Fecal S100A12 is shown to be a useful noninvasive marker of gut inflammation. However, the studies to date have not characterised the patterns of expression in healthy young children. This study aimed to determine S100A12 levels in infants and children without symptoms of underlying gut disease. Methods. Stool samples were collected from healthy infants (<12 months) and children without gastrointestinal symptoms. Faecal S100A12 was measured by immunoassay. Results. Fifty-six children were recruited. Serial samples were obtained from seven term infants over the first 6 months of life. Single samples were obtained from 49 healthy children ranging from 0.16 to 13.8 years of age. Median S100A12 levels were 0.5 mg/kg (ranging from 0.39 to 25) in the healthy children, with high values (>10 mg/kg) in five infants only. There was no variation between gender. Median S100A12 levels in healthy infants remained below the established normal cut-off from birth to six months of age. Conclusion. S100A12 levels in well infants and children are almost exclusively lower than the standard cut-off. Transiently higher levels may be seen in early infancy. An elevated level of S100A12 in children older than 12 months of age is likely to represent organic gut disease.
引用
收藏
页码:295 / 299
页数:5
相关论文
共 19 条
[11]  
Leach Steven T, 2006, Expert Rev Clin Immunol, V2, P471, DOI 10.1586/1744666X.2.3.471
[12]   The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease [J].
Lewis, James D. .
GASTROENTEROLOGY, 2011, 140 (06) :1817-U160
[13]   The Role of S100A12 as a SystemicMarker of Inflammation [J].
Meijer, B. ;
Gearry, R. B. ;
Day, A. S. .
INTERNATIONAL JOURNAL OF INFLAMMATION, 2012, 2012
[14]   ASSESSMENT OF THE NEUTROPHIL DOMINATING PROTEIN CALPROTECTIN IN FECES - A METHODOLOGIC STUDY [J].
ROSETH, AG ;
FAGERHOL, MK ;
AADLAND, E ;
SCHJONSBY, H .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1992, 27 (09) :793-798
[15]   Fecal Calprotectin Excretion in Preterm Infants during the Neonatal Period [J].
Rouge, Carole ;
Butel, Marie-Jose ;
Piloquet, Hugues ;
Ferraris, Laurent ;
Legrand, Arnaud ;
Vodovar, Michel ;
Voyer, Marcel ;
de la Cochetiere, Marie-France ;
Darmaun, Dominique ;
Roze, Jean-Christophe .
PLOS ONE, 2010, 5 (06)
[16]  
Rugtveit J, 2002, J PEDIATR GASTR NUTR, V34, P323, DOI 10.1097/00005176-200203000-00022
[17]   High Faecal Calprotectin Levels in Healthy, Exclusively Breast-Fed Infants [J].
Savino, Francesco ;
Castagno, Emanuele ;
Calabrese, Roberto ;
Viola, Serena ;
Oggero, Roberto ;
Miniero, Roberto .
NEONATOLOGY, 2010, 97 (04) :299-304
[18]   Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children [J].
Sidler, Marca A. ;
Leach, Steven T. ;
Day, Andrew S. .
INFLAMMATORY BOWEL DISEASES, 2008, 14 (03) :359-366
[19]  
Yang Z, 2001, J LEUKOCYTE BIOL, V69, P986